CRISPR and Cas Gene Global Market Report 2024

The crispr and cas gene market size has grown exponentially in recent years. It will grow from $3.28 billion in 2023 to $3.97 billion in 2024 at a compound annual growth rate (CAGR) of 21.3%. The growth observed during the historical period can be attributed to several factors, including increased consumer awareness, a shift in consumer values, the rise in celebrity endorsements, the growing popularity of veganism, and increased influence from social media platforms.

The crispr and cas gene market size is expected to see exponential growth in the next few years. It will grow to $8.37 billion in 2028 at a compound annual growth rate (CAGR) of 20.5%. The anticipated growth in the upcoming period can be attributed to several factors, including the global expansion of bans on certain ingredients, the rise of conscious consumerism, the emergence of new brands in the market, initiatives focused on consumer education, and the promotion of beauty inclusivity. Key trends expected in the forecast period encompass advancements in technology, product innovations, the development of a circular beauty economy, growth in the men's grooming segment, and an increased focus on social justice and ethical sourcing within the beauty industry.

The anticipated increase in focus on personalized therapy is set to drive the growth of the CRISPR and Cas gene markets in the future. Personalized therapy involves utilizing an individual's genetic profile to inform decisions regarding disease diagnosis, treatment, and prevention. CRISPR and the Cas gene, particularly Cas9, play a pivotal role in personalized medicine by enabling precise modifications to an individual's genetic material, offering potential breakthroughs in tailored therapies for genetic disorders, cancer, and various medical conditions. For example, data from the Personalized Medicine Coalition, a US-based professional membership organization, revealed that in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs). Among these, approximately 34%, or 12 of them, are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Thus, the growing demand for personalized therapy is expected to fuel the growth of the CRISPR and Cas gene markets.

Key players in the CRISPR and Cas gene markets are actively developing innovative products such as CRISPR-based cell-based gene therapy to enhance their product offerings and gain a competitive edge. CRISPR-based cell-based gene therapy involves utilizing CRISPR gene-editing technology to modify or correct genetic material within cells, presenting a targeted and potentially transformative approach to treating genetic disorders, diseases, and other medical conditions at the cellular level. For instance, in December 2023, Vertex Pharmaceuticals Incorporated, a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for CASGEVY (exagamglogene autotemcel [exa-cel]). CASGEVY is a CRISPR/Cas9 genome-edited gene therapy indicated for managing sickle cell disease (SCD) in individuals aged 12 and above who experience recurrent vaso-occlusive crises. This first-of-its-kind therapy has the potential to offer a one-time transformative treatment for eligible sickle cell patients. Vertex is collaborating with experienced institutions to establish a network of approved treatment centers (ATCs) across the United States to administer CASGEVY to patients, requiring specific training in stem cell transplantation.

In January 2022, Bayer AG, a Germany-based pharmaceutical company, entered into a collaboration with Mammoth Biosciences to harness the natural richness in advancing the next generation of CRISPR products. This partnership aims to utilize Mammoth's CRISPR systems for developing in vivo gene-editing therapies, enhancing Bayer's emerging cell and gene therapy platform. The collaboration aligns with Mammoth Biosciences' goal of unlocking the full potential of innovative CRISPR systems. Mammoth BioSciences is a US-based biotechnology company specializing in developing CRISPR-Cas gene diagnostic tests.

Major companies operating in the crispr and cas gene market report are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc, AstraZeneca plc., Danaher Corporation, Quest Diagnostics, Lonza Group AG, Bio-Rad Laboratories Inc., eGenesis, Novartis Institutes for BioMedical Research, Myriad Genetics Inc., GenScript, Takara Bio Inc., 23andMe Inc., Merck KGaA, Color Genomics Inc., Horizon Discovery Group Plc, Beam Therapeutics Inc, Intellia Therapeutics Inc., New England BioLabs, Recursion Pharmaceuticals Inc, Caribou Biosciences Inc., Cellectis S.A., Editas Medicine Inc.

North America was the largest region in the CRISPR and Cas gene market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr and cas gene market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the CRISPR and Cas gene market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CRISPR and Cas gene market consists of revenues earned by entities by offering services such as gene editing, targeted disruption of genes, targeted drug development, livestock breeding, and animal model construction. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR and Cas gene market also includes sales of RNA clean-up kits, phenol-free kits, t7 polymerase mix, and RNAse-free water. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, along with the Cas (CRISPR-associated) gene, particularly Cas9, represents a powerful gene-editing technology. This system enables precise modifications to DNA sequences, revolutionizing genetic research, biotechnology, and potential medical applications.

The primary product types within the CRISPR and Cas genes market include kits and enzymes, libraries, design tools, antibodies, and others. Kits and enzymes are fundamental components in the realm of CRISPR-based gene therapy, with kits containing the necessary ingredients and instruments for gene editing research, and enzymes, such as Cas9, playing a pivotal role in the gene editing process. Services are categorized into cell line engineering, gRNA design, microbial gene editing, and DNA synthesis, and find applications across clinical, financial, operational, and administrative domains. End users of these products and services include biotechnology and pharmaceutical companies, academic and government research institutes, as well as contract research organizations (CROs).

The CRISPR and Cas gene research report is one of a series of new reports that provides CRISPR and Cas gene market statistics, including the CRISPR and Cas gene industry's global market size, regional shares, competitors with a CRISPR and Cas gene market share, detailed CRISPR and Cas gene market segments, market trends and opportunities, and any further data you may need to thrive in the CRISPR and Cas gene industry. This CRISPR and Cas gene market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.